Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1α

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 801-807

  Rho, Jin Kyung ^a,b   Choi, Yun Jung ^a   Lee, Jin Kyung ^a   Ryoo, Baek Yeol ^a   Na, Im II ^a   Yang, Sung Hyun ^a   Kim, Cheol Hyeon ^a   Yoo, Young Do ^b   Lee, Jae Cheol ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Epidermal growth factor receptor; Gefitinib; Hypoxia; Hypoxia inducible factor 1 ; Lung cancer; Resistance

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PACLITAXEL; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RECEPTOR BLOCKING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 64849102022     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000287     Document Type: Article

References (40)

1. Minet E, Michel G, Remacle J and Michiels C: Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med 5: 253-259, 2000.
2. Semenza GL: Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Curr Opin Genet Dev 8: 588-594, 1998.
3. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
4. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000.
5. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
6. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9: 677-684, 2003.
7. Unruh A, Ressel A, Mohamed HG, et al: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003.
8. Le QT, Denko NC and Giaccia AJ: Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23: 293-310, 2004.
9. Hockel M, Schlenger K, Hockel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
10. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
11. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
12. Phillips RJ, Mestas J, Gharaee-Kermani M, et al: Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481, 2005.
13. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
14. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
15. Fukuda R, Hirota K, Fan F, Jung YD, Ellish LM and Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002.
16. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G and Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999.
17. Danielsen AJ and Maihle NJ: The EGF/ErbB receptor family and apoptosis. Growth Factors 20: 1-15, 2002.
18. Chrysogelos SA and Dickson RB: EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29: 29-40, 1994.
19. Scagliotti GV, Selvaggi G, Novello S and Hirsch FR: The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10: 4227s-4232s, 2004.
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. Cancer Res 47: 943-946, 1987.
21. Selvaggi G, Novello S, Torri V, et al: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15: 28-32, 2004.
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807, 2003.
23. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T and Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369, 2001.
24. Dery MA, Michaud MD and Richard DE: Hypoxia-inducible factor 1: Regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37: 535-540, 2005.
25. Ono M, Hirata A, Kometani T, et al: Sensitivity to gefitinib (iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/ extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465-472, 2004.
26. Raben D, Helfrich B, Ciardiello F and Bunn PA: Understanding the mechanisms of action of EGFR inhibitors in NSCLC: What we know and what we do not know. Lung Cancer 41: S15-S22, 2003.
27. Mazure NM, Chen EY, Laderoute KR and Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331, 1997.
28. Zundel W, Schindler C, Haas-Kogan D, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000.
29. Flugel D, Gorlach A, Michiels C and Kietzmann T: Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1 alpha and mediates its destabilization in destabilization in a VHL-independent manner. Mol Cell Biol 27: 3253-3265, 2007.
30. Sonenberg N and Gingras AC: The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10: 268-275, 1998.
31. Takata M, Ogawa W, Kitamura T, et al: Requirement for akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1). J Biol Chem 274: 20618-20618, 1999.
32. Erler IT, Cawthorne CJ, Williams KJ, et al: Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889, 2004.
33. Yeo EJ, Chun YS, Cho YS, et al: YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525, 2003.
34. Sasabe E, Tatemoto Y, Li D, Yamamoto T and Osaki T: Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96: 394-402, 2005.
35. Bos R, Zhong H, Hanrahan CF, et al: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93: 309-314, 2001.
36. Bachtiary B, Schindl M, Potter R, et al: Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9: 2234-2240, 2003.
37. Schindl M, Schoppmann SF, Samonigg H, et al: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002.
38. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia- inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
39. Kwon DS, Kwon CH, Kim JH, Woo JS Jung JS and Kim YK: Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 85: 1189-1199, 2006.
40. Lee SM, Lee CT, Kim YW, Han SK, Shim YS and Yoo CG: Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 242: 231-238, 2006.